CordenPharma, a contract development and manufacturing organization of active ingredients and drug products, and GE Healthcare’s Dharmacon business, part of the GE Healthcare Life Sciences Division, have entered a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery.

The collaboration will address the speed and capacity challenges researchers face when transitioning from research and preclinical stages to drug development and clinical trials. This changeover requires customers to move from a technology vendor to a contract manufacturing organization; compounding this step are capacity challenges in the biotech contract manufacturing marketplace.

Dharmacon has experience in custom synthesis of complex RNA oligonucleotides and chemical modifications to support research and preclinical capacity.

CordenPharma entered the oligonucleotide manufacturing field in 2016 by investing in process development, scale-up, and cGMP manufacturing at multiple scales in CordenPharma Colorado, the company’s site that supports early-stage to Phases II/III development with commercial supply capabilities expected to be operational by the end of 2017.

Source: CordenPharma